4428744

METHOD AND SYSTEM FOR EXTERNALLY TREATING THE

BLOOD

Richard L Edelson assigned to Bourke Frederic A; Bourke Eleanor; Edelson Richard L; The Edelson Tru

A method and system are disclosed for ex- ternally treating human blood, with the objective of reducing the functioning lymphocyte popula- tion in the blood system of a human subject. According to the method, blood is withdrawn from the subject and passed through an ul- traviolet radiation field in the presence of from about I nanogram to 100 micrograms per ml of blood, of a dissolved photoactive agent capable of forming photo-adducts with lymphocytic- DNA, mobile cortisone receptors or antigen sites to thereby effect covalent bonding between the photoactive agent and the same, thereby in- hibiting the metabolic processes of the lympho- cytes or complexing them; and thereupon returning the irradiated blood to the subject. The withdrawn blood may be formed into an extra- corporeal stream and flowed through a treat- ment station whereat the irradiation is effected, as for example by exposure to UV radiation; and such flow process may be conducted on a con-

Healthcare Products

tinuous basis. If desired, at least portions of the treated blood may then be separated. as for ex- ample by a continuous centrifuge. before retur- ning the remaining diverted blood to the subject.

4429115

3-0-OLEANDROSYL-5-0- DESOSAMINYL

ERYTHRONOLIDE COMPOUNDS

Leonardo M Cappelletti. Roberto Spagnoli, Luciano Toscano assigned to Pierre1 S p A

0

The fermentation of a substrate selected among erythronolide B, erythronolide A and erythrono- lide A oxime with a novel mutant, Streptomyces antibioticus ATCC 31771, obtained from an industrial stock for the production of olean- domycin, said novel mutant being incapable of producing the same oleandomycin, permits novel macrolide antibiotics to be produced, having not only an activity range like that of erythromycin, but characterized by a greater stability in acidic environment, whereby for the administration of antibiotic it is no longer neces- sary to have recourse to esters and/or salts highly toxic for the organism.

PATENT ABSTRACTS 133

4430437

TEST METHODS EMPLOYING MONOCLONAL ANTIBODIES AGAINST HERPES SIMPLEX

VIRUS TYPES 1 AND 2 NUCLEOCAPSIDS PROTEINS

Berge Hampar, Martin Zweig, Harvey Rabin, Conrad Heilman. Ralph Hopkins, Russell H Neubauer assigned to- The United States of America as represented by the Department of Health and Human Services

The method of producing clinical assays for use of monoclonal-antibodies in the diagnosis of Heroes simplex virus (HSV) infections and the differentiatibn of Herpes Simplex virus types 1 and 2 as a diagnostic kit for differentiating HSV- I and HSV-2 utilizing clone ID4 against HSV-I and clone 3El against HSV-2.

4430495

PROCESS FOR PREPARING LINCOMYCIN AND

CLINDAMYCIN RIBONUCLEOTIDES

Tom E Patt, Alexander D Argoudelis. Vincent Marshall assigned to The Upjohn Company

OH

Novel and useful ribonucleotides of analogs of the well known antibiotics lincomycin and clin- damycin. These ribonucleotides are unexpec- tedly highly active against Streptococcus hemolyticus and Staphylococcus aureus in vivo. These ribonucleotides are prepared by using resting cell or cell-free extracts of Streptomyces rochei, NRRL 3533. or cell-free extracts of Streptomyces coelicolor. NRRL 3532.

4433061

RADIOIMMUNOASSAY FOR CYCLIC NUCLEOTIDES

Chih-Sheng Chiang assigned to American Hospital Supply Corporation

An improved radioimmunoassay for the deter- mination of cyclic nucleotides in body fluids which comprises adding a source of divalent ca- tion prior to assay minimizes the effects of both endogenous calcium ion and EDTA used as an anticoagulant in blood plasma samples.

4434156

MONOCLONAL ANTIBODIES SPECIFIC FOR THE HUMAN TRANSFERRIN RECEPTOR

GLYCOPROTEIN

Ian S Trowbridge assigned to The Salk Institute for Biological Studies

Monoclonal antibodies are produced specific for the cell surface transferrin receptor of human cells. Animals are inoculated with purified human transferrin receptor glycoprotein, human hematopoietic cells or fragments thereof, and spleen cells obtained from the animals are fused with myeloma cells to produce hybridomas. The hybridomas are cultured as clones, and anti- bodies obtained from the individual clones are tested for their specificty for human transferrin receptor. Clones which produce antibodies specific for the receptor and that interfere with or block transferrin binding are selected for further culturing to produce the antibody, and the anti- body is obtained from the culture growth medium or from ascitic fluid of an animal bearing a tumor of the hybridoma. Monoclonal antibodies which block transferrin binding are useful in regulating cell growth and for other therapeutic uses.

134 PATENT ABSTRACTS

4434230

HUMAN NONSECRETORY PLASMACYTOID CELL LINE

Roy E Ritts assigned to Research Corporation

A human non-secretory plasmacytoid con- tinuous cell line, established for five years in more than I50 passages, is karyotypically nor- mal, easily grown and has the characteristic features of a plasmablast excepting for its secretory defect, and can be used for the prepara- tion of human-human hybridomas with human B-lymphocytes and separation of the resulting hybridomas from the plasmacytoma cell line by growth in COZ-containing media, or by fluores- cence activated cell sorting, or both.

4438032

UNIQUE T-LYMPHOCYTE LINE AND PRODUCTS DERIVED

THEREFROM

David Golde, Shirley G Quan assigned to The Regents of the University of California

Human T-lymphoblast cell line, Proteinaceous products produced therefrom, messenger RNA and DNA expressing the proteinaceous pro- ducts. A human T-lymphoblast cell line (MO) maintained as a continuous culture constitu- tively produces proteins, including immune interferon, neutrophil migration inhibition fac- tor, granulocyte-macrophage colony- stimulating activity and erythroid-potentiating activity, as well as other proteins produced by T- cells.

4440857

PROCESS FOR PREPARING MYCAROSYLTYLACTONE

Eugene T Seno, Richard H Baltz, Norwich, IN, United Kingdom assigned to Eli Lilly and Com- pany

CHz-CH) OH

CH>

0

if

OH

0

CHJ

A new microorganism, Streptomyces fradiae NRRL 12201. which produces mycarosyltylac- tone (50-mycarosyl-20-dihydro-20.23- dideoxytylonolide) and a process for preparing tylactone (20-dihydro-20.23-dideoxytylonolide) and mycarosyltylactone by submerged aerobic fermentation of this microorganism, or a mycarosyltylactone-producing mutant or recombinant thereof, are provided.

4442085

PROTECTION AGAINST DENTAL CARIES

Geoffrey Colman, Roy R B Russell, Sevenoaks, United Kingdom assigned to The Secretary of State for Social Services in Her Britannic Majesty’s Government of the United Kingdom of Great Britain and Northern Ireland

An antigenic protein, termed antigen A, present on the cell walls and in cultures of Streptococcus mutans. especially genetic group I (serotypes c, e and f) is separated from other antigenic proteins, notably those which cross-react with heart tis- sue. to give an antigenic preparation which may be used as a vaccine or to raise antibodies for use in protecting against dental caries. Antigen A is one of two major antigenic proteins remaining on cell walls of S. mutans genetic group I after extraction with a boiling IO g/l liter aqueous solution of sodium dodecyl sulphate for 20 minutes. It has a molecular weight of about 29,000, an isoelectric point of 4.1 to 4.5. Its amino-acid analysis is also given. The antigen also occurs in the culture filtrate and/or cell extract and may be readily purified from these sources by, for example fractional ammonium sulphate precipitation and/or affinity chromatography on immobilized antibody.

4443427

MONOCLONAL ANTIBODY

Ellis L Reinherz, Stuart F Schlossman assigned to Sidney Farber Cancer Institute Inc

Monoclonal antibodies specific to a mature human T cell surface antigen of molecular weight of about 120,000 daltons as determined by electrophoresis, the antigen not being modulated by monoclonal antibodies specific to it and being restricted within the human lymphoid system to the surface of mature T cells, the monoclonal antibodies being capable of

PATENT ABSTRACTS 135

selectively binding mature human T cells and rendering them inactive in vivo and failing to in- duce the proliferation or activation of human lymphocytes.

4443431

NEISSERIA GONORRHOEAE VACCINE

Thomas Buchanan, Willia Pearce, Kirk C S Chen assigned to The United States of America as represented by the Department of Health and Human Services

A vaccine affording protection against attach- ment of Neisseria gonorrhoeae (N.g.) to human cells, and consequent infection, is prepared from a fragment of pili protein isolated from gonococci. This fragment contains the shared antigens between pili from different N.g., in an exposed form.

4443549

PRODUCTION OF MONOCLONAL ANTIBODIES

AGAINST BACTERIAL ADHESINS

Peter L Sadowski assigned to Molecular Gene- tics Inc

Monoclonal antibodies specific for surface anti- gens of bacteria which act as adhesins between prokaryotic and eukaryotic cells and, in par- ticular, K-99 pili, and methods for production thereof are described. These monoclonal anti- bodies may be used for the prophylactic and therapeutic treatment of diseases induced by adhesin-bearing pathogens in animals and humans, and for the diagnostic identification of adhesin-bearing bacteria..

4444683

GLYCOSYLATED INSULIN DERIVATIVES

Wan S Kim, Seo Jeong, James McRea assigned to University of Utah

r FHzOH 1

Synthesized succinyl and glutaryl glucosamines. p-(succinylamido)-phenyl- alpha-D-gluco- and mannopyranosides. p-(glutarylamido)-phenyl- alpha-D-gluco- and mannopyranosides and p- (isothiocyanotophenyl)- alpha-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins con- taining from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.

4444744

TUMOR LOCALIZATION AND THERAPY WITH LABELED

ANTIBODIES TO CELL SURFACE ANTIGENS

Milton D Goldenberg

Improved methods are provided for using radiolabeled antibodies to tumor cell surface antigens to locate, diagnose and stage tumors having such antigens on their cell surfaces by ex- ternal photoscanning, whereby significantly in- creased resolution, convenience and/or efficiency of operation may be achieved. A method is provided for using highly specific radiolabeled antibodies to cell surface antigens for tumor therapy. Radiolabeled antibodies and injectable compositions containing them are provided for use in the method of the invention.

4444757

USE OF THYMOSIN AS AN ANTI-DIABETES AND ANTI-

HYPERTENSIVE DISEASE AGENT

Helen R Strausser assigned to Research Cor- poration

Methods are provided for the use of Thymus gland extracts, such as Thymosin, fraction 5, as an anti-autoimmune disease agent, useful in treating autoimmune diseases such as hyperten- sion, lupus and diabetes. Thymosin, fraction 5, administration stimulated the development of a specific subclass of Thymus derived cells called Thymus suppressor cells which reduced the autoimmune state, thereby reducing hyperten- sion, lupus, diabetes, and other autoimmune dis- eases.

136 PATENT ABSTRACTS

4444758

NONAPEPTIDE FOR TREATING ADDICTIVE DRUG

WITHDRAWAL CONDITIONS

Richard R Scherschlicht. Renacu/e/ Tissot, In- zlingen, Federal Republic Of Germany assigned to Hoffmann-La Roche Inc

A nonapeptide and its pharmaceutically ac- ceptable salts are described for the treatment of addictive drug withdrawal conditions.

4444759

GNRH ANTAGONISTS II

Jean E F Rivier, Wylie Vale assigned to The Salk Institute for Biological Studies

Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Ad- ministration of an effective amount prevents ovulation of female mammalian eggs and/or the release of steroids by the gondads. The peptides have the structure. X- beta-D-2NAL-R2-D-Trp- Ser-RS-R6-R7-Arg-Pro-R10 wherein X is hydrogen or an acvl grouu having 7 or less car- bon aibms; R2 is Cl-D-Phe, F-DIPhe, N02-D- Phe. CIZ-D-Phe or Br-D-Phe: RS is Tvr or CI- Phef R6 is 4-NHZ-D-Phe or D-Arg; R7;s Leu or N alphaMe-Leu; and RlO is Gly-NH2. NHCHZCH3 or D-Ala-NH2

4444760

PURIFICATION AND CHARACTERIZATION OF A

PROTEIN FIBROBLAST GROWTH FACTOR

Kenneth Thomas assigned to Merck & Co Inc

Acidic brain fibroblast growth factor isolated from bovine brain, is purified by a particular combination of protein purification techniques. The product is useful in the promotion of cell division (mitogenesis) such as in the promotion of wound healing.

4444878

BISPECIFIC ANTIBODY DETERMINANTS

Henry P Paulus assigned to Boston Biomedical Research Institute Inc

_.~~7

_L- -3 -5

7 x 3 1z

C&~ I -

&Y , %F ._, i,! A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab’) portion of a mono- clonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and enzyme electrodes.

INSULIN MEDIATOR SUBSTANCE

Joseph Larner, Kang Cheng, Gail Galasko as- signed to The University of Virginia Alumni Pa- tents Foundation

An insulin mediator substance produced by the process comprising: contacting muscle tissue with insulin; deproteinizing the muscle tissue; removing the major nucleotides from the deproteinized muscle tissue; chromatographing the so-treated product on a Sephadex G-25 column using 0.05 N formic acid; and recovering the fraction wherein the major 230-nm abs- orbance peak corresponds with the ninhydrin- positive peak.

4446129

METHOD FOR TREATMENT OF ARTHROSIS DEFORMANS WITH

ELASTASE

Tohru Sawada, Ibaragi. Japan assigned to Eisai Co Ltd

A method is disclosed for treating a subject suf- fering from arthrosis deformans which com-

PATENT ABSTRACTS 137

prises administering to said subject a therapeutically effective amount of a composi- tion comprising elastase and a pharma- cologically acceptable carrier. Particularly excellent results were obtained using this method for the treatment of gonarthrosis deformans.

4446144

DERIVATIVES OF PENICILLANIC ACID

Welf von Daehne, Rungsted Kyst, Denmark as- signed to Leo Pharmaceutical Products Ltd A/S (Lovens Kemiske Fabrik Pro- duktionsaktieselskab)

This invention relates to penicillanic acid derivatives of the formula I See Putenrfor Chem- icul Structure I in which X stands for chlorine, bromine or iodine, to pharmaceutically ac- ceptable, non-toxic salts of the compounds of formula I, to pharmaceutically acceptable, easily hydrolyzable esters thereof, including salts of such esters, to pharmaceutical compositions containing the compounds of the invention and dosage units thereof, to methods for the prepara- tion of the compounds of the invention, and to methods of using the said new compounds in the human and veterinary therapy. The 6 beta- halopenicillanic acids of formula I are potent in- hibitors of beta-lactamases from a variety of gram-positive and gram-negative bacteria, making the 6 beta-halopenicillanic acids as well as their salts and easily hydrolyzable esters valuable in human and veterinary medicine.

4446230

TEST METHOD FOR THE LABORATORY DIAGNOSIS OF

GONORRHEA AND TEST STRAIN OF NEISSERIA GONORRHOEAE

Leonard J Zubrzycki assigned to Temple University of the Commonwealth System of Higher Education

A strain of Neisseria gonorrhoeae ATCC 3 1953 is described which is abnormal in that it has characteristically poor growth on chocolate agar at a temperature range of about 30 degrees C. to about 37 degrees C. in a CO2 atmosphere suitable for growth of N. gonorrhoeae. This strain is resistant to nalidixic acid at the 5-10 mcg/ml level and resistant to streptomycin at the 1000 mcgiml level or greater. N. gonorrhoeae

ATCC 3 1953 is a test strain suitable for use in the method described for the laboratory diagnosis of gonorrhea. The method comprises the steps of (1) applying a non-toxic preparation of a patient’s specimen material, directly to a culture of Neisseria gonorrhoeae ATCC 31953, which has abnormal growth characteristics, which is in or on a biological medium suitable for growth of normal Neisseria gonorrhoeae, and observing for the restoration of normal growth to the ab- normal growth strain Neisseria gonorrhorae ATCC 31953, in or on the biological medium of step (I), under conditions normal for growth of Neisseria gonorrhoeae. The observence of growth indicates positive detection of N. gonorr- hoeae DNA.

4446234

VITRO CELLULAR INTERACTION WITH AMNION MEMBRANE

SUBSTRATE

Raimondo Russo, Lance A Liotta assigned to The United States of America as represented by the Department of Health and Human Services

Amnion membranes derived from mammalian placentas are employed as the substrate tissue in in vitro assay methods for evaluating cellular interaction with natural barrier tissues. The amnion is also employed as a growth substrate, particularly for the culture of cells difficult to culture on conventional substrates. A diagnostic apparatus including an amnion membrane is also disclosed.

4446237

METHOD FOR DETECTION OF A SUSPECT VIRAL

DEOXYRIBONUCLEIC ACID IN AN ACELLULAR BIOLOGICAL

FLUID

Mark S Berninger assigned to Life Technologies Inc

There is disclosed a method for evaluating ac- ellular biological fluid for viral DNA, such as

138 PATENT ABSTRACTS

DNA of the Hepatitus-B virus, whereby the ac- ellular biological fluid is treated to immobilize in denatured form the DNAs including the suspect viral DNA on a solid support or substrate with the resulting solid substrate being contacted with a solution including radioisotropically-labeled viral denatured DNA followed by analysis of solid substrate for radioisotopically-labeled suspect viral renatured DNA.

4450103

PROCESS FOR RECOVERING HUMAN IFN- BETA FROM A

TRANSFORMED MICROORGANISM

Michael W Konrad, Leo S Lin assigned to Cetus Corporation

OH

H,C-CHZ-C-CH,

b

A process for recovering IFN- beta from trans- formed bacteria comprising: disrupting the cell membranes of the bacteria; solubilizing the IFN- beta from the disruptate into an aqueous medium with a solubilizing agent such as sodium dodecyl sulfate; extracting the IFN- beta from the aqueous medium with 2-butanol, 2-methyl- butanol, or mixtures thereof under conditions that maintain phase separation between the aqueous meduim and the extractant; and isolating the IFN- beta from the extractant such as by precipitating the IFN- beta from an aqeous buffer mixture of the extractant by lowering the pH thereof.

4450153

ALCOHOL REMOVAL FROM BLOOD WITH ALCOHOL

OXIDASE

Thomas R Hopkins assigned to Phillips Petro- leum Company

The level of alcohol content (methanol or ethanol) in blood is reduced by contacting the blood alcohol with the enzyme alcohol oxidase. Injection, extracorporeal shunt (dialysis), and oral administration are contemplated as routes of administration. Suitable compositions for reducing the blood alcohol level are also pro- vided.

4451446

PROCESS FOR THE PREPARATION OF

POLYSACCHARIDE-PROTEIN COMPLEXES FROM BACTERIAL

CAPSULES, OBTAINED PRODUCTS AND IMMUNOGENIC

COMPOSITIONS CONTAINING THEM

Jean Vandevelde, Robert De Neys, Ottignies Louvain la Neuve, Belgium assigned to Smithkline-Rit

Process for the non-degrading preparation of polysaccharide-protein complexes from bac- terial capsules; the so-obtained products which are useful as vaccines against infection by the same bacteria and method for protecting human beings against the same infection by administra- tion of pharmaceutical composition containing the polysaccharide-protein complexes.

4451570

IMMUNOGLOBULINSECRETING HUMAN HYBRIDOMAS FROM A

CULTURED HUMAN LYMPHOBLASTOID CELL LINE

Ivor Royston, Harold Handley, J Edwin Seeg- miller, Lmda F Thompson assigned to The Re- gents of the University of California

Novel human lymphoblastoid cells and hybridomas derived therefrom are provided. The cells are a HGPRT negative human B-ceil line. The cells are readily fusible with lymphoid cells to produce hybridomas which secrete human monoclonal antibodies.